12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AmpliVue regulatory update

Quidel said FDA granted 510(k) clearance for AmpliVue to detect toxigenic Clostridium difficile bacterial DNA. The...

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >